bg-logo-sd
bg-icon-sd
February 2025

Eli Lilly Bets Big on Weight-Loss Pill With $550 Million Inventory Stockpile

J&J faces investor skepticism amid unresolved baby powder lawsuits. Kevin Gade of Bahl & Gaynor highlights the unpredictability of such legal battles and their hidden impact on business.

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in “pre-launch inventory” in its financial statements, a filing showed on Wednesday.

Kevin T. Gade
Chief Operating Officer Principal & Portfolio Manager
kgade@bahl-gaynor.com

Continue reading more HERE to hear insights from Bahl & Gaynor’s very own, Kevin Gade.

Contact Us

© Copyright 2025 | Bahl & Gaynor, 255 East Fifth Street, Suite 2700 Cincinnati, OH 45202
Linkedin-in X-twitter

You're Leaving

You are now leaving the Bahl & Gaynor main website and entering into the Active ETFs website. By continuing to this link, we are not making any representation, warranty, or endorsement about the website and we are not providing you with investment advice or offering securities for sale to you.

Cancel
Continue